Gastroesophageal Reflux Disease Market Predicted To See Upsurge Through 2034, Highlights Delveinsight
Gastroesophageal Reflux disease market Insights. DelveInsight's Gastroesophageal Reflux Disease Market report offers an in-depth understanding of the epide ...
Phathom spikes as Cantor Fitzgerald bullish on IP claims
Phathom Pharmaceuticals (PHAT) stock rises as Cantor Fitzgerald issues an Overweight rating, rejecting its IP-rights related ...
Phathom Pharmaceuticals initiated at Cantor Fitzgerald on ‘significant’ upside
Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target The firm cited ...
Phathom Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target Maximize Your Portfolio ...
Stifel maintains $28 target on Phathom Pharmaceuticals stock
Stifel analysts have maintained a Buy rating and a $28.00 price target for Phathom Pharmaceuticals (NASDAQ:PHAT), focusing on the company's recent developments. Currently trading at $5.59, ...
gastroenterologyadvisor17d
Treating Erosive Esophagitis With Potassium-Competitive Acid Blockade
LA grades C and D are considered severe GERD. Treatment of EE With Proton Pump Inhibitors Nonsevere GERD can often be managed with lifestyle modifications and medication, whereas patients with more ...